SCHEMBL4479249

SCHEMBL4479249

O=C(O)Cn1c(Cc2ccco2)ccc1-c1ccccc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 15/20 0.62
HSD17B10 Q99714 15/20 0.62
ALDH1A1 P00352 15/20 0.62
MAPT P10636 6/20 0.62
PKM P14618 2/20 0.62
HPGD P15428 5/20 0.58
POLB P06746 8/20 0.51
KMT2A Q03164 4/20 0.51
ALOX15 P16050 4/20 0.51
MEN1 O00255 3/20 0.51
USP2 O75604 2/20 0.51
ALOX12 P18054 2/20 0.51
MAPK1 P28482 1/20 0.51
GAA P10253 2/20 0.45
GLA P06280 1/20 0.45
RCE1 Q9Y256 1/20 0.45
APEX1 P27695 3/20 0.45
L3MBTL1 Q9Y468 3/20 0.45
RECQL P46063 1/20 0.45
CASP6 P55212 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27699451 0.83 KDM4E (0.50) KDM4EHSD17B10ALDH1A1MAPTPKM
SCHEMBL4483851 0.82 KDM4E (0.49) KDM4EHSD17B10ALDH1A1MAPTPKM
SCHEMBL8269691 0.82 KDM4E (0.52) KDM4EHSD17B10ALDH1A1MAPTPKM
SCHEMBL4491252 0.80 KDM4E (0.68) KDM4EHSD17B10ALDH1A1MAPTPKM
SCHEMBL4494789 0.75 KDM4E (0.69) KDM4EHSD17B10ALDH1A1PKMHPGD
SCHEMBL4468097 0.74 KDM4E (0.47) KDM4EHSD17B10ALDH1A1MAPTPKM
SCHEMBL5503526 0.68 KDM4E (0.59) KDM4EHSD17B10ALDH1A1PKMHPGD
SCHEMBL20248207 0.68 KDM4E (1.00) KDM4EHSD17B10ALDH1A1MAPTPKM
SCHEMBL8269516 0.67 ALDH1A1 (0.66) KDM4EHSD17B10ALDH1A1MAPTPKM
SCHEMBL27699452 0.66 KDM4E (0.70) KDM4EHSD17B10ALDH1A1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7488832-B2 e.g. N-[amino(imino)methyl]-2-[2-(4-phenoxyphenyl)-5-phenyl-1H-pyrrol-1-yl]acetamide; beta -amyloid deposits and neurofibrillary tangles; cognition activator, neurodegenerative diseases; Alzheimer's disease, Down's syndrome WYETH (US) 2009-02-10 US disclosed
US-20060183790-A1 Azolylacylguanidines as beta-secretase inhibitors WYETH (US) 2006-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183790-A1 Azolylacylguanidines as beta-secretase inhibitors BACE1, BACE2, APP KDM4E 1462/4885HSD17B10 933/4885ALDH1A1 360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.